Latest Blog Posts
Search
Sort Results
Filter by Specific Population
Filter by Topic
Filter by Infection
- HIV (remove)
Filter by Resource Category
- Research summary (remove)
Search results
Current filters: HIV, Treatment, Research summary, HIV drugs, Raltegravir (Isentress, Isentress HD)
10 search results
- CDC recommends use of raltegravir (Isentress) for PEP
-
From TreatmentUpdate 228
2018, CATIE
Research summary - Webpage - Isentress HD in clinical trials
-
From TreatmentUpdate 221
2017, CATIE
Research summary - Webpage - Isentress HD—a new once-daily formulation of raltegravir approved in Canada
-
From TreatmentUpdate 221
2017, CATIE
Research summary - Webpage - Canadian researchers review the use of raltegravir in pregnancy
-
2016, CATIE
Research summary - Webpage - U.S. study reviews use and impact of integrase inhibitors in pregnancy
-
2016, CATIE
Research summary - Webpage - Comparing the tolerability and effectiveness of initial therapy
-
From TreatmentUpdate 202
2014, CATIE
Research summary - Webpage - Dual therapy with raltegravir and darunavir
-
From TreatmentUpdate 202
2014, CATIE
Research summary - Webpage - Raltegravir in women and reduced soluble CD14
-
From TreatmentUpdate 201
2014, CATIE
Research summary - Webpage - Dolutegravir vs. raltegravir—results after two years
-
From TreatmentUpdate 199
2013, CATIE
Research summary - Webpage - Australia: raltegravir and muscle weakness—a rare complication
-
From TreatmentUpdate 193
2012, CATIE
Research summary - Webpage
